The vascular biology of nitric oxide and its role in atherogenesis

Annual Review of Medicine

Volumn 47, Issue , 1996, Pages 365-375

  Lloyd Jones, Donald M ^a   Bloch, Kenneth D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Endothelium; Endothelium derived relaxing factor; Neointimal formation; Restenosis; Signal transduction

Indexed keywords

CYCLIC GMP; ENDOTHELIUM DERIVED RELAXING FACTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL PROLIFERATION; HOMEOSTASIS; HUMAN; LEUKOCYTE FUNCTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON; ANIMALS; ARTERIOSCLEROSIS; CYCLIC GMP; ENDOTHELIUM, VASCULAR; FIBROMUSCULAR DYSPLASIA; HUMANS; NITRIC OXIDE; RECURRENCE; SIGNAL TRANSDUCTION;

EID: 0029983521     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.47.1.365     Document Type: Review

References (52)

1. Palmer RMJ, Ferrige AG, Moncada S. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-26
2. Nathan C, Xie Q. 1994. Nitric oxide synthases: roles, tolls, controls. Cell 78: 915-18
3. Stamler JS, Singel DJ, Loscalzo J. 1992. Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898-902
4. Stamler JS, Jaraki O, Osborne J, et al. 1992. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc. Natl. Acad. Sci. USA 89:7674-77
5. Busse R, Mulsch A, Fleming I, et al. 1993. Mechanisms of nitric oxide release from the vascular endothelium. Proc. Natl. Acad. Sci. USA Circulation 87(Suppl. V): V18-V25
6. Mohaupt MG, Elzie JL, Ahn KY, et al. 1994. Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int. 46:653-65
7. Bloch KD, Wolfram JR, Brown DM, et al. 1995. Three members of the nitric oxide synthase II gene family co-localize to human chromosome 17. Genomics 27: 526-30
8. Furchgott RF, Zawadzki JV. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-76
9. Lincoln TM. 1989. Cyclic GMP and mechanisms of vasodilatation. Pharmacol. Ther. 41:479-502
10. Palmer RMJ. 1993. The discovery of nitric oxide in the vessel wall. Arch. Surg. 128: 396-401
11. Gardiner SM, Compton AM, Bennett T, et al. 1990. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 15:486-92
12. Rees DD, Palmer RMJ, Moncada S. 1989. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. USA 86:3375-78
13. Vane J, Anggard EE, Botting RM. 1990. Regulatory functions of the vascular endothelium. N. Engl. J. Med. 323:27-36
14. Panza JA, Quyyumi AA, Brush JE, et al. 1990. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 323: 22-27
15. Nava E, Palmer RMJ, Moncada S. 1991. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet 338:1555-57
16. Petros A, Bennett D, Vallance P. 1991. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338:1557-58
17. Ross R. 1993. The pathogenesis of athero sclerosis: a perspective for the 1990s. Nature 362:801-8
18. Fuster V. 1994. Lewis A. Conner Memorial Lecture: Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90:2126-46
19. Vita JA, Treasure CB, Nabel EG, et al. 1989. The coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81: 491-97
20. Reddy KG, Nair R, Sheehan HM, et al. 1994. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J. Am. Coll. Cardiol. 23: 833-43
21. Anderson TJ, Gerhard MD, Meredith IT, et al. 1995. Systemic nature of endothelial dysfunction in atherosclerosis. Am. J. Cardiol. 75:B71-B74
22. Hogg N, Kalyanaraman B, Joseph J, et al. 1993. Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS 334:170-74
23. Chang GJ, Woo P, Honda HM, et al. 1994. Oxidation of LDL to a biologically active form by derivatives of nitric oxide and nitrite in the absence of superoxide. Arterioscler. Thromb. 14:1808-14
24. Radomski MW, Moncada S. 1993. The biological and pharmacological role of nitric oxide in platelet function. In Mechanisms of Platelet Activation and Control, ed. KS Authi, pp. 251-64. New York: Plenum
25. Bath PMW, Hassall DG, Gladwin A-M, et al. 1991. Nitric oxide and prostacyclin. Arterioscler. Thromb. 11:254-60
26. Bath PMW. 1993. The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. Eur. J. Clin. Pharmacol. 45:53-58
27. Lefer AM, Ma X. 1993. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler. Thromb. 13:771-76
28. Kubes P, Suzuki M, Granger DN. 1991. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA 88:4651-55
29. Garg UC, Hassid A. 1989. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83:1774-77
30. Scott-Burden T, Vanhoutte PM. 1993. The endothelium as a regulator of vascular smooth muscle proliferation. Circulation 87(Suppl. V):V51-V55
31. Hassid A, Arabshahi H, Boucier T, et al. 1994. Nitric oxide selectively amplifies FGF-2-induced mitogenesis in primary rat aortic smooth muscle cells. Am. J. Physiol. 267:H1040-48
32. Cayatte AJ, Palacino JJ, Horten K, et al. 1994. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thomb. 14:753-59
33. Naruse K, Shimizu K, Muramatsu M, et al. 1994. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. Arterioscler. Thromb. 14:746-52
34. Cooke JP, Singer AH, Tsao P, et al. 1992. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 90:1168-72
35. Wang B-Y, Singer AH, Tsao PS, et al. 1994. Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J. Am. Coll. Cardiol. 23: 452-58
36. Ludmer PL, Selwyn AP, Shook TL, et al. 1986. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315: 1046-51
37. Drexler H, Zeiher AM, Meinzer K, et al. 1991. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 338:1546-50
38. Dubois-Rande J-L, Zelinsky R, Roudot F, et al. 1992. Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Am. J. Cardiol. 70:1269-75
39. Creager MA, Gallagher SJ, Girerd XJ, et al. 1992. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. 90:1248-53
40. Guo J-P, Milhoan KA, Tuan RS, et al. 1994. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimal injury. Circ. Res. 75:77-84
41. von der Leyen HE, Gibbons GH, Morishita R, et al. 1995. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA 92: 1137-41
42. Joly GA, Schini VB, Vanhoutte PM. 1992. Balloon injury and interleukin-1 B induce nitric oxide synthase activity in rat carotid arteries. Circ. Res. 71:331-38
43. Hansson GK, Geng Y, Holm J, et al. 1994. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J. Exp. Med. 180:733-38
44. Schini VB, Vanhoutte PM. 1993. Role of the L-arginine-nitric oxide pathway in vascular smooth muscle. Eur. Heart J. 14 (Suppl. 1):16-21
45. McNamara DB, Bedi B, Aurora H, et al. 1993. L-Arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem. Biophys. Res. Commun. 193:291-96
46. Hamon M, Vallet B, Bauters C, et al. 1994. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 90:1357-62
47. Werner-Felmayer G, Werner ER, Fuchs D, et al. 1993. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cGMP. J. Biol. Chem. 268:1842-46
48. Leung W-H, Lau C-P, Wong C-K. 1993. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 341:1496-500
49. Egashira K, Hirooka Y, Kai H, et al. 1994. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89: 2519-24
50. Treasure CB, Klein JL, Weintraub WS, et al. 1995. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332:481-87
51. Anderson TJ, Meredith IT, Yeung AC, et al. 1995. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332:488-93
52. Superko HR, Krauss RM. 1994. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 90:1056-69